Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Merck's Anti-TL1A Antibody Scores Win in Hidradenitis Suppurativa Trial

Guavy AI Editorial Team
Instruments
MRK
Share

Merck's anti-TL1A antibody has scored a win in treating hidradenitis suppurativa, but failed in a rare lung disease. The company made the announcement after conducting mid-stage trials for the treatment.

Hidradenitis suppurativa is a chronic skin condition characterized by painful bumps and abscesses. Merck's anti-TL1A antibody was tested on patients with this condition and showed promising results, but more data is needed to confirm its effectiveness.

On the other hand, the antibody failed to show any benefit in treating a rare lung disease. The trial aimed to test the treatment in patients with this specific condition, but unfortunately, it did not meet its goals.

More on Stocks

Stocks just now

Tech Giants Cut Thousands of Jobs Amid AI-Driven Restructuring

Stocks just now

Microsoft Expands Xbox Backward Compatibility to Include Classic Xbox 360 Games

Stocks just now

Microsoft Extends Gains as Crude Oil and Gold Trade Mixed

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Real-time market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy